Septerna, Inc.

NASDAQ:SEPN

Biotechnology

Healthcare
$39.45 -2.04%

-$0.73 today

Market cap
$1.88B
Beta
2.38
P/E (TTM)
-43.6
EPS (TTM)
-$0.81
52W Low $9.96High $37.32

Volume 0.30M

Average 0.32M

SEPN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Septerna, Inc.NASDAQ: SEPN

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin narrows to 0.0%

Gross margin was 0.0% in Q3 FY2026, down 100.0 pp from a year earlier. On a trailing-twelve-month basis it was 79.9%, down 20.1 pp year over year.

Context

  • Gross margin widened in 0 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
0.0%-100.0 pp QoQ
Last fiscal yearDec 2025
100.0%+0.0 pp YoY
LTMSep 2026
79.9%-20.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-100.0 pp——
1 year+0.0 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How SEPN compares with its peers on the latest reported figures

  • SEPN's LTM Sep 2026 gross margin of 79.9% is the lowest of the 3 companies compared; the peer median is 96.0%.
  • Its year-over-year change of -20.1 pp is the lowest of 3, against a peer median of +60.7 pp.
SEPN Competitors Peer median
Gross Margin for SEPN and competitors
Company Period LTM level YoY 3-year change
VTVTvTv Therapeutics Inc.LTM Mar 2026100.0% +129.4 pp—
MAZEMaze Therapeutics, Inc.LTM Mar 202692.0% -8.0 pp—
SEPNSepterna, Inc.LTM Sep 202679.9% -20.1 pp—
MBXMBX Biosciences, Inc. Common StockFY2025— ——
KLRAKailera Therapeutics, Inc.FY2025— ——
GPCRStructure Therapeutics Inc.FY2025— ——
BMEABiomea Fusion, Inc.FY2025— ——
Peer median (excluding SEPN) 96.0%+60.7 pp—

Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue151K1.08M45.95M
Cost of Revenue000
Gross Profit151K1.08M45.95M
Gross Margin100.0%100.0%100.0%
Research & Development35.98M65.34M97.58M
Selling, General & Admin9.72M16.56M29.16M
Operating Expenses(1.92M)81.9M126.75M
Depreciation & Amortization848K1.4M1.6M
EBITDA(44.7M)(70.9M)(47.26M)
EBITDA Margin-29604.0%-6594.9%-102.9%
Operating Income2.08M(80.82M)(80.8M)
Operating Margin1374.2%-7518.4%-175.8%
Interest Income2.79M8.62M19.53M
Interest Expense000
Other Income / Expenses2.8M8.53M31.93M
Income Before Tax4.87M(72.3M)(48.87M)
Pre-Tax Margin3225.8%-6725.2%-106.3%
Income Tax Expense691K(498K)12K
Net Income4.18M(71.8M)(48.88M)
Net Margin2768.2%-6678.9%-106.4%
EPS (Basic)0.03(1.93)(1.10)
EPS (Diluted)0.03(1.93)(1.10)
Weighted Avg Shares19.5M37.19M44.26M
Weighted Avg Shares (Diluted)19.5M37.19M44.26M

Septerna, Inc.

NASDAQ:SEPN

Intrinsic Alpha fair value

Locked

Current Price

$39.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.